What is CGEM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CGEM?

P/E (TTM) is n/a and 52-week range is $6.50 to $23.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CGEM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CGEM?

The company profile lists net income (TTM) near $-209M, EPS (TTM) near $-3.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cullinan Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 61.5M shares outstanding, ISIN US2300311063 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cullinan Therapeutics Inc

$CGEM

Health Care · Biotechnology

IR Run Scenarios

$15.53

+0.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 109 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Employees

109

Website

cullinantherapeutics.com/

IPO

2021-01-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)